Menu

Blog

Archive for the ‘biotech/medical’ category: Page 297

Feb 6, 2024

An Integrated Approach to Evaluate Acetamiprid-induced Oxidative Damage to tRNA in Human Cells based on Oxidized Nucleotide and tRNA Profiling

Posted by in categories: biotech/medical, life extension, neuroscience

Acetamiprid-induced oxidative stress can harm DNA and tRNA, leading to health problems. A study conducted by Huixia Zhang at Macau University of Science and Technology in 2023 introduced a comprehensive approach to assessing acetamiprid-induced oxidative damage to tRNA in human cells through oxidized nucleotide and tRNA profiling. Acetamiprid, a modern insecticide, is known for causing oxidative stress and related toxicity. Despite its impact on oxidative stress, the effects of acetamiprid-induced oxidative stress on RNA, especially tRNA, remained unexplored until this study.

Acetamiprid was found to elevate reactive oxygen species (ROS) production in HepG2 and LO2 cells, contributing to mitochondrial damage, free radical generation, and antioxidant status depletion. Oxidative damage to DNA and RNA can harm organisms, with prior research addressing RNA damage in aging, neurodegenerative diseases, and mental illnesses. However, its role in acetamiprid-induced toxicities has not been investigated.

The study employed TMSD labeling-based LC-MS/MS to measure oxidized nucleotide levels in HepG2 and LO2 cells treated with two mM acetamiprid. It also examined the impact of acetamiprid on the 8-oxo-G content of tRNAs and created volcano plots to compare RNase T1 digestion products of tRNAs from untreated and acetamiprid-treated cells.

Feb 6, 2024

This remarkable project sequences 100,000 genomes from circa 85,000 patients affected by rare disorders and cancers – making the UK a world leader in genomic medicine

Posted by in category: biotech/medical

Feb 6, 2024

Surprise find: a blood-based immune system is discovered in the gut

Posted by in category: biotech/medical

Immune guardians called complement proteins are manufactured by gut cells and help to protect against pathogens.

Feb 6, 2024

Scientists 3D Print Functional Human Brain Tissue

Posted by in categories: 3D printing, biotech/medical, neuroscience

A team of scientists at the University of Wisconsin-Madison claim to have 3D-printed functional human brain tissue for the first time.

They hope their research could open the doors for the development of treatments for existing neurological disorders, including Alzheimer’s and Parkinson’s disease.

As detailed in a new paper published in the journal Cell Stem Cell, the team flipped the usual method of 3D-printing on its side, fabricating horizontal layers of brain cells encased in soft “bio-ink” gel.

Feb 6, 2024

AI Can Design Totally New Proteins From Scratch—It’s Time to Talk Biosecurity

Posted by in categories: biotech/medical, robotics/AI

Two decades ago, engineering designer proteins was a dream.

Now, thanks to AI, custom proteins are a dime a dozen. Made-to-order proteins often have specific shapes or components that give them abilities new to nature. From longer-lasting drugs and protein-based vaccines, to greener biofuels and plastic-eating proteins, the field is rapidly becoming a transformative technology.

Custom protein design depends on deep learning techniques. With large language models—the AI behind OpenAI’s blockbuster ChatGPT—dreaming up millions of structures beyond human imagination, the library of bioactive designer proteins is set to rapidly expand.

Feb 5, 2024

Can Patients with Low-Risk

Posted by in category: biotech/medical

Staphylococcus aureus bacteremia have their antibiotic treatment switched early from IV to oral?


Switching to oral antibiotic therapy can be as effective as prolonged intravenous (IV) therapy for several infections, including bone and joint infections and endocarditis (NEJM JW Infect Dis Jan 30 2019 and N Engl J Med 2019; 380:425; NEJM JW Gen Med Apr 14 2020 and JAMA Intern Med 2020; 180:769). European investigators now report results of an open-label, controlled noninferiority trial comparing a switch to oral antibiotics or continued IV treatment after 5 to 7 days of IV therapy in individuals with low-risk Staphylococcus aureus bacteremia (e.g., clearance of bacteremia within 72 hours, no evidence of deep-seated focus). Total duration of therapy was 14 days; oral options were trimethoprim-sulfamethoxazole, clindamycin, or linezolid; IV options were flucloxacillin, cefazolin, vancomycin, or daptomycin).

The trial was terminated after 213 of 5,063 screened individuals had been enrolled over a 6-year period. Oral therapy was found to be noninferior to IV therapy (in both intention-to-treat and clinically evaluable analyses) for the primary composite outcome of complications from S. aureus infection within 90 days. Two deaths due to S. aureus bacteremia occurred (both in the oral switch group), and 34% of the oral switch group versus 26% of the IV group had a serious adverse event (P=0.29) that was most commonly infectious.

Continue reading “Can Patients with Low-Risk” »

Feb 5, 2024

Shared molecular pathways found in Alzheimer’s and epilepsy

Posted by in categories: biotech/medical, neuroscience

🧠 🔬 💡


Study reveals shared brain proteomic signatures in Alzheimer’s disease and epilepsy, suggesting common molecular mechanisms that could pave the way for unified therapeutic strategies.

Feb 5, 2024

An AI System for the Detection and Incidence Prediction of Chronic Kidney Disease

Posted by in categories: biotech/medical, health, mobile phones, robotics/AI

The creation of an artificial intelligence (AI) system that can analyze retinal fundus images to detect chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) represents a groundbreaking advancement in medical technology. This AI model, developed using a substantial dataset of retinal images and advanced convolutional neural networks, has demonstrated exceptional accuracy in identifying these conditions. Its capability extends beyond mere detection, as it also shows promise in predicting the progression of these diseases based on retinal imaging and clinical metadata.

A notable innovation of this AI system is its ability to analyze smartphone images. This feature significantly enhances the accessibility of sophisticated diagnostic tools, especially in regions with limited healthcare resources. The AI model paves the way for more widespread and convenient health screenings by enabling ubiquitous smartphone technology for medical imaging. This development is particularly impactful in enhancing healthcare delivery and access, as it brings critical diagnostic capabilities into the hands of more people, even in remote or underserved areas.

The AI’s proficiency in predicting the future development of CKD and T2DM is another aspect of its novelty. This predictive ability is crucial for timely intervention, potentially altering the trajectory of these chronic illnesses. Early detection and management are vital in battling CKD and T2DM, and this AI model’s predictive power could significantly improve patient outcomes.

Feb 5, 2024

What are MEMs? (Micro Electro Mechanical Systems)

Posted by in categories: biotech/medical, mobile phones, nanotechnology, robotics/AI

Micro Electro Mechanical Systems (MEMS) are miniature devices that integrate mechanical elements, sensors, actuators, and electronics on a single silicon chip. These systems serve diverse applications, such as accelerometers in smartphones, gyroscopes in navigation systems, and pressure sensors in medical devices. MEMS devices can detect and respond to environmental changes, enabling the creation of smart, responsive technologies. Their small size, low power consumption, and ability to perform various functions make MEMS crucial in fields like telecommunications, healthcare, automotive, and consumer electronics. Learn more about this tiny machines with this video!

#science #technology #microscopic #nanotechnology #robotics #engineering

Feb 5, 2024

Researchers identify the basic principles of serotonin transport in nerve cells

Posted by in categories: biotech/medical, neuroscience

Drugs known as antidepressants target the serotonin transporter in nerve cells and are among the most commonly prescribed medicines worldwide, but are sometimes associated with significant side effects. As part of a study, a research group led by Thomas Stockner from MedUni Vienna identified the basic principles of serotonin transport and thus created a possible basis for the development of novel drugs with improved selectivity and with fewer undesirable effects. The results were recently published in the renowned scientific journal “Nature Communications”

While the desired effects of drugs unfold through the interaction with the relevant target structures, the undesirable side effects are often due to a lack of selectivity and therefore due to interactions with other target structures. Accordingly, developing drugs that can differentiate between the various physiologically relevant targets (e.g. transporters and receptors) is one of the challenges for research. A team led by Ralph Gradisch under the supervision of Thomas Stockner from MedUni Vienna’s Center for Physiology and Pharmacology set out to find a way to increase selectivity for the serotonin transporter while reducing interaction with other targets at nerve cells in the brain.

Page 297 of 2,751First294295296297298299300301Last